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Philippe Montravers6, Jordi Rello7, Andrew Rhodes8, Therese Starr2, Steven C Wallis1 and Jeffrey Lipman1,2Abstract
Background: The clinical effects of varying pharmacokinetic exposures of antibiotics (antibacterials and antifungals)
on outcome in infected critically ill patients are poorly described. A large-scale multi-centre study (DALI Study) is
currently underway describing the clinical outcomes of patients achieving pre-defined antibiotic exposures. This
report describes the protocol.
Methods: DALI will recruit over 500 patients administered a wide range of either beta-lactam or glycopeptide
antibiotics or triazole or echinocandin antifungals in a pharmacokinetic point-prevalence study. It is anticipated that
over 60 European intensive care units (ICUs) will participate. The primary aim will be to determine whether
contemporary antibiotic dosing for critically ill patients achieves plasma concentrations associated with maximal
activity. Secondary aims will compare antibiotic pharmacokinetic exposures with patient outcome and will describe
the population pharmacokinetics of the antibiotics included. Various subgroup analyses will be conducted to
determine patient groups that may be at risk of very low or very high concentrations of antibiotics.
Discussion: The DALI study should inform clinicians of the potential clinical advantages of achieving certain
antibiotic pharmacokinetic exposures in infected critically ill patients.
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Effective antibiotic treatment of intensive care unit (ICU)
patients that have overwhelming infections, including sep-
sis, severe sepsis and septic shock, remains a significant
challenge to physicians world-wide [1-7]. Therapy that is
not initiated rapidly or with sufficient antibiotic spectrum
increases in-hospital mortality [3,4]. Indeed, sepsis itself
has an incidence in the population that exceeds colon* Correspondence: j.roberts2@uq.edu.au
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reproduction in any medium, provided the orcancer, breast cancer, and AIDS, with mortality rates of
30% for mild to moderate sepsis and up to 82% for severe
sepsis and septic shock [5]. Despite advances in critical
care medicine, the incidence of sepsis continues to in-
crease and the prognosis remains poor. Although there
has been significant investment into treatments that limit
the various inflammatory and coagulation cascades, none
of these therapies have been able to demonstrate the same
outcome benefits as effective antibiotic therapy [3,8]. It is
thought that optimisation of antibiotic dosing may well
further improve clinical outcomes for ICU patients with
infections.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and then extrapolated into ICU patients. A challenge
for clinicians is that standard dosing in ICU patients
does not achieve the same concentrations seen in non-
critically ill patients [9]. There is a significant body of
literature that demonstrates that disease-processes experi-
enced by critically ill patients frequently cause pharmaco-
kinetic changes that may result in either sub-therapeutic
or toxic drug concentrations of antibiotics (including anti-
bacterial and antifungal drugs) [9-17]. Given the increased
level of resistance of bacteria in the ICU [18], and these
potentially lower antibiotic exposures, treatment failure of
infections is unsurprisingly common. Subtherapeutic drug
concentrations may also promote selection of resistant
microorganisms, further adding to the threat of anti-
biotic resistance in the ICU. To address this issue in-
novative approaches to dosing may be required to
ensure optimal drug exposures [19-21].
Although altered antibiotic concentrations have been
accurately described in various critically ill patient sub-
populations in small research studies [21-28], there is
no large multi-centre evaluation that seeks to determine
whether the issues identified in a controlled research
environment correspond to clinical practice. Such an
evaluation is essential for determining whether action
is required to change existing global antibiotic prescribing
practices for critically ill patients. If prescribing should be
found to be sub-optimal, then the motivation for changes
to existing prescribing practice may lead to improved clin-
ical cure rates and a reduction in the rate of antibiotic re-
sistance in the critical care environment. To address the
insufficiency of data available to clinicians on the ade-
quacy of empiric antibiotic dosing in ICU patients, on be-
half of the Infection Section of the European Society of
Intensive Care Medicine, the authors proposed a multi-
centre point-prevalence pharmacokinetic study in ICU
patients.
This proposal has been supported by the European
Society of Intensive Care Medicine’s European Critical
Care Research Network (ESICM ECCRN) and Trials
Group and also the the Royal Brisbane and Women’s
Hospital Research Foundation (Australia). This report
describes the study protocol.
Based on our previous research in many different criti-
cally ill patient sub-populations, we hypothesize that 40
to 70% of critically ill patients are receiving suboptimal
antibiotic dosing [23,27-33].
Methods/Design
The Defining Antibiotic Levels in Intensive care unit pa-
tients (DALI) study is a prospective, multi-centre phar-
macokinetic point-prevalence study describing whether
contemporary antibiotic dosing in ICU patients achieves
concentrations associated with maximal activity. It isanticipated that the study will recruit over 500 ICU
patients from over 60 ICUs throughout 10 countries in
Europe over a one-week period. The primary and secon-
dary aims as well as the proposed sub-group analyses are
as follows:
Primary aim
 To determine whether contemporary antibiotic
dosing for critically ill patients achieves
concentrations associated with maximal activity.
Secondary aims
 Comparison of observed antibiotic
pharmacokinetics/pharmacodynamics with the
clinical outcome of therapy
 Description of the population pharmacokinetics of
the individual antibiotics in ICU patients
The proposed subgroups for the primary and second-
ary aims are:
 Patients administered intermittent dosing versus
extended or continuous infusions and
 Patients with ‘steady-state’ versus ‘non-steady-state’
pharmacokinetics (‘non-steady-state’ defined as
antibiotics commenced within 24-h prior to sampling)
 Patients with different levels of sickness severity as
measured by Sequential Organ Failure Assessment
(SOFA) Score[34], Acute Physiology and Chronic
Health Evaluation (APACHE) II Score[35] and PIRO
(Predisposition, Infection, Response, Organ
dysfunction) Score[36]
 Different admission diagnoses
 Different indications for antibiotic therapy
 Presence of surgery within the 24-hours prior to
sampling
 Different total body weight
 Different levels of renal function and presence of
extracorporeal renal support techniques
Participants
Identification of eligible patients will occur on a desig-
nated day (preferably Monday) of a nominated week. In-
formed consent is required from each patient or a legally
authorised representative to participate in the study. Parti-
cipants would need to fulfil all the inclusion and exclusion
criteria to be enrolled:
Inclusion criteria
 Written informed consent has been obtained from
the patient or their legally authorised representative
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 Receiving antibiotic therapy of one of the target
drugs via continuous or intermittent dosing regimen
 Suitable intravenous/intra-arterial access to facilitate
sample collection
Exclusion criteria
 Consent not obtained
 Aged < 18 years of age
 Not being administered any of the study antibiotics
 Limited or no intravenous/intra-arterial access.
Study treatments and pharmacokinetic sampling
With the exception of blood sampling, there is no inter-
vention in this study that may affect patient treatment.
Antibiotic dosing will occur as deemed by the treating
clinician and their local dosing practices. Patients recei-
ving the study antibiotics will be identified on the nomi-
nated week for pharmacokinetic sampling. During a
single dosing interval of that week, each patient will then
have two blood samples taken for each antibacterial agent
and/or three blood samples for antifungals (Table 1). For
patients on multiple study drugs, each drug will be
sampled independent of the other drug(s). Table 1 outlines
the test antibiotics (antibacterials and antifungals) to be
sampled, the timing of pharmacokinetic sampling and theTable 1 Study drugs, routes of administration, pharmacokine
Study Drugs and method of infusion Pharm
Beta-lactam antibiotics by intermittent infusion Sampl
(50% o
(amoxycillin-clavulanate; ampicillin; piperacillin-tazobactam;
penicillin-G; flucloxacillin; dicloxacillin; cloxacillin; cephazolin;
ceftazidime; ceftriaxone; cefepime; meropenem; imipenem;
doripenem; ertapenem)
Sampl
(100%
Glycopeptide antibiotics by intermittent infusion
(vancomycin, teicoplanin)
Triazole antifungals (fluconazole, voriconazole) Sampl
infusio
Echinocandin antifungals (caspofungin, micafungin, anidulafungin) Sampl
(50% o
Sampl
(100%
Beta-lactam antibiotics (listed above) by continuous infusion Sampl
SamplGlycopeptide antibiotics (listed above) by continuous infusion
* denotes the primary endpoint – other stated pharmacodynamics targets are seco
f T>MIC is the duration of a dosing interval for which the antibiotic concentration re
suspected pathogen (endpoints of 50% or 100% of the interval, and MIC is defined
the antibiotic concentration remains above a concentration that is 4 x the MIC of th
and MIC is defined by EUCAST MIC90 data); AUC0-24/MIC is the ratio of the area undpharmacodynamics endpoints that will be tested for each
antibiotic and dosing regimen.
The blood sampling has been designed to determine
drug concentrations at various time points to describe
whether pharmacokinetic/pharmacodynamic targets are
achieved in individual patients (Table 1). To achieve the
endpoint 50% f T>MIC, sample A is taken mid-way
through the dosing interval to see if the drug concentra-
tion exceeds the MIC. The 100% f T>MIC endpoint is
similarly assessed from the sample B taken at the end of
the dosing interval. The endpoint 100% f T>4xMIC, is
attained if all sample concentrations exceed the MIC by
at least a factor of four. For the parameter AUC0-24/
MIC, the Area Under the concentration-time Curve
from 0–24 h (AUC0-24) is calculated by the trapez-
oidal rule, and to attain the stated endpoint, the
AUC0-24 must exceed the MIC by the factor listed in
Table 1. Where the MIC not known, the MIC of the
infecting pathogen will be defined by The European
Committee on Antimicrobial Susceptibility Testing
(EUCAST) MIC90 data; available at: http://www.
eucast.org/clinical_breakpoints).
Data collection and management
Data collection will be conducted by trained staff at each
participating centre and entered onto a case report formtic/pharmacodynamic targets and blood sampling
acokinetic Sampling Pharmacodynamic
Targets tested
e A: mid-way through dosing interval
f dosing interval)
• 50% f T>MIC
e B: within 30 min of next dose
of dosing interval)
• 50% f T>4xMIC*
• 100% f T>MIC
• 100% f T>4xMIC
• 100% f T>4xMIC
• Concentration ≥15 mg/L*
e A: 30 min after completion of intravenous
n (peak concentration)
• AUC0-24/MIC ≥25*
e B: mid-way through dosing interval
f dosing interval)
• AUC0-24/MIC ≥20*
e C: within 30 min of next dose
of dosing interval)
e A: at any time • 100% f T>4xMIC*
e B: >6 hours after sample A • 100% f T>4xMIC*
• AUC0-24/MIC ≥350
ndary endpoints.
mains above the minimum inhibitory concentration (MIC) of the known or
by EUCAST MIC90 data); f T>4xMIC is the duration of a dosing interval for which
e known or suspected pathogen (endpoints of 50% or 100% of the interval,
er the concentration time curve from 0–24 hours to MIC.
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will be sent to the coordinating centre (The University
of Queensland, Australia). Outstanding queries regarding
the completion of the CRF will be undertaken with each
participating centre where necessary to ensure accuracy of
data.
The data to be collected includes.
Demographic data
 Age
 Gender
 Height
 Weight
Clinical data
 Admission diagnosis,
 Sickness severity scores (APACHE II, SOFA, PIRO)
 Presence of extracorporeal circuits (e.g. RRT (renal
replacement therapy), ECMO (extracorporeal
membrane oxygenation))
 Procalcitonin (where available),
 Presence/absence of surgery within previous 24
hours
 Clinical outcome of infection
 Mortality at 30-days
Organ function data
 Renal function – serum creatinine concentration
during studied dosing interval; MDRD (modified
diet in renal disease) equation
 8-hours urinary creatinine clearance (where
available)
 Fluid balance for total length of stay and previous
24-hours
Antibiotic dosing data
 Dose and frequency
 Time of dosing and sampling
 Day of antibiotic therapy
Infection data
 Known or presumed pathogen
 Known or likely minimum inhibitory concentration
(MIC)
The definitions used to assess clinical outcome of thera-
py are as follows. A positive clinical outcome of therapy is
defined as completion of treatment course without changeor addition of antibiotic therapy, and with no additional
antibiotics commenced with 48 h of discontinuation of
the antibiotic therapy.
De-escalation is defined as the change to a narrower
spectrum antibiotic based on patient-specific microbio-
logical data in the absence of clinical failure. For antibio-
tics that are ceased before the end of treatment of an
infection because of antibiotic de-escalation, these antibio-
tics will be excluded from the a priori analysis. Where de-
escalation occurs during the target week of sampling, an
option for a second sampling period of the new antibiotic
will exist to confirm appropriateness of antibiotic con-
centrations and compare these with the patient’s clinical
outcome.
Safety data will be collected to define any adverse drug re-
action (clinically observed, haematological or biochemical)
that is reported by the clinical staff at the participating ICUs
that is suspected as being caused by any of the study
antibiotics.
Maintenance of blood sample integrity
Blood samples will be kept on ice, centrifuged at 3000 rpm
for 10-min, within 6 h of collection and the plasma trans-
ferred to a labelled cryo-vial for frozen storage (at −20°C or
lower for short term storage). A commercial courier com-
pany specialising in transport of clinical samples on dry ice
will collect the samples from each site and deliver to the
Burns Trauma and Critical Care Research Centre at The
University of Queensland, Australia for bioanalysis. Sam-
ples will be stored at −80°C until assay.
Bioanalysis
The concentration of the study antibiotics in the biological
samples will be determined by chromatographic methods
(HPLC and LC-MS/MS) that are validated and conducted
in accordance with the US Food and Drug Administra-
tion’s guidance for industry on bioanalysis (available at:
www.fda.gov/downloads/Drugs/GuidanceCompliance
RegulatoryInformation/Guidances/UCM070107.pdf ).
Ethical issues
Each of the participating centres has obtained local ethics
approvals to conduct the study as described in Additional
file 1. The University of Queensland is the head institution
with ethical approval granted by the Medical Research
Ethics Committee (201100283 12th April 2011 and
Amendment 201100283 25th May 2011). Patients may
withdraw from the study at any time without prejudice, as
documented and explained at the time of consenting.
Statistical and pharmacokinetic analysis
The achievement of the pharmacodynamics targets will
be performed by visual inspection of the results and com-
parison with the target. Statistical analyses to test the
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U tests or Students t-tests where appropriate using the
statistical package, SPSS (version 17.0, Illinois, USA).
The % f T>MIC will be determined using the equation
[37]:
%fT>MIC ¼ ln Dose= Vd MICð Þ½   1=kelð Þ  100=DIð Þ
where Vd is volume of distribution calculated as Dose/
AUC; MIC is the known or suspected minimum inhibi-
tory concentration; kel is the elimination rate constant
calculated from the gradient of the concentration-time
curve in the elimination phase (sample A and sample B)
and DI is the dosing interval (h). Where infections are
polymicrobial, the MIC of the least susceptible pathogen
will be used in the analysis.
The population pharmacokinetic parameters of each
antibiotic will be determined using a population pharma-
cokinetic modelling approach using NONMEM® (Version
6.1, GloboMax LLC, Hanover, MD, USA) as previously
described[22,23,25,29,32,38]. Additionally, the pharmaco-
kinetic model will aim to determine if significant corre-
lations exist between demographic and clinical factors on
pharmacokinetics. If one or more of the variables are
found to have a significant effect on the pharmacokinetics
of the drug, then it can be incorporated into the final
pharmacokinetic model.Sample size and power
Whilst it is not possible to predict the number of patients
receiving each of the study antibiotics, all data will be use-
ful and can be used to inform clinical practice. It is likely
that at least 5 of the study antibiotics will have a minimum
of 30 patients included in the analysis. This sample size
will provide a power of 80% (assuming an α of 0.05 and r2
of 30%) for defining at least 2–4 covariates predictive of
achieving the primary pharmacodynamic outcome [39].
For all other included study antibiotics, we estimate that
each will have a minimum of 12 patients that can be used
for the secondary objectives of population pharmacoki-
netic analysis. A minimum of 12 patients per antibiotic is
based on data from previous non-interventional pharma-
cokinetic studies in critically ill patients [22,23,32,40].Funding
This project has received funding from the European So-
ciety of Intensive Care Medicine’s European Critical Care
Research Network (ESICM ECCRN), and the Royal Bris-
bane and Women’s Hospital Foundation. Dr Roberts is
funded by a Training Research Fellowship from the Na-
tional Health and Medical Research Council of Australia
(569917).Discussion
ICU patients are greatly different in many ways to non-
critically ill patients. Principal differences relate to the
level of sickness severity, the number of therapeutic inter-
ventions used, the severe pathophysiological changes that
occur and the presence of highly resistant bacteria and
fungi. For these reasons, it unsurprising that ICU patients
have poor outcomes associated with infections. Whilst
early and appropriate treatment of infections significantly
reduces patient mortality, the additional benefits of op-
timised antibiotic pharmacokinetic exposures have been
poorly quantified. ICU pharmacokinetic studies have tra-
ditionally only enrolled small patient numbers, which
greatly limits the ability to describe the significant interpa-
tient pharmacokinetic variability that is present, and what
effect this may have on clinical efficacy. Using a multi-
national approach to enrol large patients numbers on a
wide range of commonly used antibiotics, including both
antibacterials and antifungals, the DALI study will address
these knowledge gaps.Additional file
Additional file 1: The location of the participating sites (country
and city) and Ethics committee approving conduct of the study in
each site.
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